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W e r e p o r t  a  n o v e l p o s t - t r a n s la t io n a l  m o d i f ic a t io n  i n ­
v o lv in g  h a lo g e n a t io n  o f  t r y p to p h a n  in  p e p t id e s  r e c o v ­
e r e d  f ro m  th e  v e n o m  o f  c a r n iv o r o u s  m a r in e  c o n e  s n a i ls  
(C o n u s ). T h e  r e s id u e ,  L -6 -b ro m o try p to p h a n , w a s  i d e n t i ­
f ie d  in  th e  s e q u e n c e  o f  a  h e p ta p e p t id e ,  i s o la te d  fro m  
C o n u s  im p e r ia l is ,  a  w o r m - h u n t in g  c o n e . T h is  p e p t id e  
d o e s  n o t  e l ic i t  g ro s s  b e h a v io r a l  s y m p to m s  w h e n  in je c te d  
c e n t r a l ly  o r  p e r ip h e r a l ly  in  m ic e . L -6 -B ro m o try p to p h a n  
w a s  a ls o  id e n t i f ie d  in  a  3 3 -a m in o  a c id  p e p t id e  f ro m  C o­
n u s  r a d ia tu s ;  t h i s  p e p t id e  h a s  b e e n  s h o w n  to  in d u c e  a  
s le e p - lik e  s t a te  in  m ic e  o f  a l l  a g e s  a n d  is  r e f e r r e d  to  a s  
b r o m o s le e p e r  p e p t id e .  T h e  s e q u e n c e s  o f  th e  tw o  p e p ­
t id e s
P ca -C y s-G ly -G ln -A la -T rp * -C y s-N H 2
Sequence 1
a n d
1 5  10 15 
Trp*-Ala-Thr-Ile-Asp-Gla-Cys-Gla-Gla-Thr-Cys-Asn-Val-Thr-Phe-





w e r e  d e te r m in e d  u s in g  a  c o m b in a t io n  o f  m a s s  s p e c t r o m ­
e tr y ,  a m in o  a c id , a n d  c h e m ic a l  s e q u e n c e  a n a ly s e s ,  
w h e r e  P c a  =  p y ro g lu ta m ic  a c id , H y p  =  h y d r o x y p r o ­
l i n e ,  G la  =  y - c a r b o x y g lu t a m a te ,  a n d  T rp *  =  l-6 -  
b r o m o t r y p to p h a n .  T h e  p r e c i s e  s t r u c t u r e  a n d  s t e r e o ­
c h e m is t r y  o f  th e  m o d if ie d  r e s id u e  w e r e  d e te r m in e d  a s  
L -6 -b ro m o try p to p h a n  b y  s y n th e s is ,  c o -e lu tio n , a n d  e n z y ­
m a t ic  h y d ro ly s is  e x p e r im e n ts .  T o  o u r  k n o w le d g e  t h i s  is  
t h e  f i r s t  d o c u m e n ta t io n  o f  t r y p to p h a n  r e s id u e s  in  p e p ­
t id e s /p r o te in s  b e in g  m o d if ie d  in  a  e u k a r y o t ic  s y s te m  
a n d  th e  f i r s t  r e p o r t  o f  h a lo g e n a t io n  o f  t r y p to p h a n  in  
v ivo .
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Polypeptides encoded by genes are prim arily made up of the 
20 common amino acids th a t are directly transla ted  using the 
genetic code. However, m any of these amino acids can be fur­
ther modified post-translationally to yield a set of additional 
amino acids th a t contribute to the function of the m ature pro­
tein. Together the 20 prim ary amino acids and these “second­
ary” amino acids which are found in proteins comprise the set 
of proteinogenous amino acids.
These modified amino acids include amino acid conjugates 
where the side chain is linked to a glycosyl, phosphate, or 
sulfate group and amino acids such as 5-hydroxylysine, 4-hy- 
droxyproline, and Y-carboxyglutamate. One notable set of mod­
ified amino acids are halogenated derivatives of tyrosine and 
histidine. N aturally  occurring halogenated tyrosine and h isti­
dine residues have previously been identified from proteins 
(1-4). A particularly well documented example of in vivo post- 
translational halogenation of an amino acid residue in  a pro­
tein  is afforded by thyroglobulin (5). After iodination of several 
tyrosine residues, selective cleavages release the iodinated thy­
roid hormones thyroxine (3,5,3',5'-tetraiodothyronine or T4)1; 
3,5,3'-triiodothyronine (T3), and 3,3'-di-iodothyronine. The 
presence of free T3 and T4 has also been shown in protochor- 
dates, suggesting a primitive thyroid function exists in tuni- 
cates (2).
Of the 20 common amino acids, alanine, glycine, isoleucine, 
leucine, and valine, which lack side chain functional groups, 
have not been implicated in post-translational modifications 
(6). In 1907 it was proposed th a t hydroxytryptophan was a 
proteinogenous amino acid (7), bu t th is proposal has not been 
verified (1), and chemical oxidation of tryptophan is likely to be 
responsible for the observed modification. More recently, Takai 
and Hayaishi (8) have described tryptophan side chain oxi­
dases in Pseudomonas, while M clntire et al. (9) have described 
a redox co-factor which is covalently linked to 2 tryptophan 
residues in Methylobacterium extorquens and Thiobacillus ver- 
sutus. In th is report, we establish, using accepted criteria (1 0 -
1 The abbreviations used are: T4, 3,5,3',5 '-tetraiodothyronine; T3, 
3,5,3'-tri-iodothyronine; Boc, fert-butoxycarbonyl; Cys(Cam), S-car- 
boxyamidomethylcysteine; Cys(Mob), S-p-methoxybenzyl-L-cysteine; 
CZE, capillary zone electrophoresis; DCM dichloromethane; DIC, diiso- 
propylcarbodiimide; DIEA, diisopropylethylamine; Gln(Xnt), N Y-xan- 
thyl-L-glutamine; HOBt, 1-hydroxybenzotriazole; HPLC, high perform­
ance liquid chromatography; LSI, liquid secondary ionization; MALD, 
m atrix-assisted laser desorption; MS, m ass spectrometry; NMP, N- 
methylpyrrolidone; TBTU, 0-(benzotriazol-1-yl)N,N,N ',N '-tetramethy- 
luronium  tetrafluoroborate; TCEP, tris-(2-carboxyethyl)phosphine. 
Amino acids are indicated by the standard  three le tter abbreviations 
unless otherwise indicated.
























Fig. 1. S h e lls  o f  C. im p e r ia l i s  a n d  C. r a d ia tu s  c o lle c te d  in  th e
P h ilip p in e s . The two brom inated peptides described in  this report 
were isolated from the venom duct of these species of carnivorous 
m arine snails. C. im peria lis  hun ts m arine worms, whereas C. ra d ia tu s  
feeds on vertebrate fish. Reported shell lengths are 40-105 mm (im pe­
ria lis)  and 40-77 mm (radiatus).
12), th a t 6-bromotryptophan is a secondary amino acid and 
establish its presence in two peptides purified from the venoms 
of two Conus species, the imperial cone, Conus imperialis, and 
the radial cone, Conus radiatus (Fig. 1).
Most conotoxins are small, highly constrained and special­
ized polypeptides present in the venom produced by m arine 
cone snails (Conus) (13). A distinctive characteristic of the 
conotoxins is the high percentage of cysteine residues m ediat­
ing disulfide bridges in  m any of the peptides. The disulfide 
bridges are responsible for the highly constrained conforma­
tions of these toxins enabling the molecules to block a variety  of 
different receptors w ith high binding affinity and selectivity. 
These peptides also have high levels of other modified amino 
acids including hydroxy proline and 7-carboxyglutamic acid 
(14). To this list we now add 6-bromotryptophan.
EXPERIMENTAL PROCEDURES 
Reagents
The following reagents were used: DIC (Chem-Impex International, 
Wood Dale, IL); DCM (Fisher); Boc-Ala-OH, Boc-Cys(Mob)-OH, Boc- 
Gln(Xnt)-OH, Boc-Gly-OH, pGlu-OH, Boc-Thr(OBzl)-OH, and Boc- 
Ala-OH (Bachem, Torrance, CA); DL-6-bromotryptophan (Biosynth
A.G., S taad, Switzerland); DL-5-bromotryptophan (synthesized as de­
scribed elsewhere (15)); acetyl chloride (99 + %), anisole, ascorbic acid, 
hexyl alcohol (98%), HOBt, iodine, and piperidine (Aldrich); DIEA 
(Fisher); TBTU and N-methylpyrrolidone (Advanced Chemtech, Louis­
ville, KY); HF (Matheson Gas Products, Cucamonga, CA); trifluoroace­
tic acid (Halocarbon Products Corp., River Edge, NJ); ether, acetoni­
trile, and acetic acid (Mallincrodt Baker Inc., Paris, KY); m ethanol 
(Burdick and Jackson Division, Muskegon, MI); TCEP (synthesized by 
the m ethod of Burns e t al. (16)); iodoacetamide, EDTA, guanidine hy­
drochloride, Hepes, sodium carbonate, 4-vinyl pyridine, Tris-HCl, and 
Tris base (Sigma); £-m ercaptoethanol (Pierce); a-chym otrypsin, ami- 
nopeptidase-M , carboxypeptidase-Y, endoproteinase Lys-C, endopro- 
teinase  Asp-N, and  pyroglutam ate am inopeptidase (Boehringer 
M annheim).
Crude Venom
The crude venom was obtained from C. im peria lis  and C. ra d ia tu s  by 
dissection of the venom duct gland and was stored a t —70 °C.
Peptide Purification
Pooled venom was diluted w ith 0.1% aqueous trifluoroacetic acid and 
injected onto a  reverse phase high performance liquid chromatography 
(HPLC) using a  Vydak C ^  column (10 x  250 mm, 5 ^m  particle size, 
Rainin Instrum ents, Woburn, MA) and eluted w ith a  linear gradient of 
acetonitrile in  0.085% trifluoroacetic acid a t 5 mL/min. The HPLC
apparatus consisted of HPXL pumps and either a  Dynamax model UVI 
or UV-DII detector (Rainin Instrum ents). Subsequent purification steps 
utilized a  Cj8 Microsorb or C ^  Vydac column, 4.6 x  250 mm, 5 ^m  
particle size (Rainin Instrum ents). The effluents were m onitored a t 220 
nm. Peaks were collected, and aliquots were assayed for activity.
Bioassays
Biological activity of both the heptapeptide and the bromosleeper 
peptide was assayed by in tracran ial and in traperitoneal injection in 
mice (9-22 days old) as described previously (17). Aliquots of peptide 
sam ples were lyophilized and suspended in  norm al saline solution, 
th en  injected into mice using  a  0.3-ml syringe w ith a  29-gauge needle. 
Twenty-microliter volumes were injected intracranially, and 50-^l vol­
umes were injected intraperitoneally. Each control mouse was injected 
with an  equal volume of norm al saline solution containing dissolved 
residue of lyophilized column buffer. After injections, the mice were 
placed in  cages for observation.
Enzyme Hydrolysis
P AP  H ydro lysis—The brom oheptapeptide was incubated in  a  0.1 M 
Na2CO3 solution with pyroglutam ate aminopeptidase (1:1, enzyme:sub- 
strate) a t 37 °C for 17 h.
E ndoproteinase Lys-C  H ydrolysis—Fragm ents of the pyridylethyl- 
ated  sleeper peptide were generated by digestion with endoproteinase 
Lys-C. The peptide was incubated with the enzyme in a  total volume of 
50 ^ l (25 mM sodium bicarbonate buffer, pH 8.5, 10% acetonitrile) at 
37 °C for 16 h. The reaction was stopped by addition of 25 ^l of aceto­
nitrile and 5 of 10% trifluoroacetic acid and the digest purified with 
HPLC.
E ndoproteinase A sp -N  H ydro lysis—Fragm ents of the pyridylethyl- 
ated  sleeper peptide were generated by digestion with endoproteinase 
Asp-N. The peptide was incubated with the enzyme in  a  total volume of 
50 ^ l (25 mM potassium  phosphate buffer, pH 8, 10% acetonitrile) at 
37 °C for 19 h. The reaction was stopped by addition of 25 ^l of aceto­
nitrile and 5 of 10% trifluoroacetic acid and the digest purified with 
HPLC.
A m inopeptidase-M  H ydro lysis—The synthetic 1 -4  bromosleeper N- 
term inal fragm ent (100 pmol) was incubated in  100 of 100 mM Hepes 
solution with 20 m illiunits of aminopeptidase-M a t 24 °C and the reac­
tion monitored with HPLC at 24-h and 4-day time points.
Chemical Modifications
E sterifica tion—Esterification of the N-term inal (1-4) fragm ent of the 
bromosleeper peptide with acidic hexanol, prepared from acetyl chloride 
and hexyl alcohol, was carried out as outlined elsewhere (18).
R eduction  a n d  A lk y la tio n —The brom oheptapeptide was reduced 
with 10 mM TCEP in  200 mM sodium acetate buffer, pH 5, and alkylated 
w ith iodoacetamide in 30 mM Tris base, pH 10, containing 2 mM EDTA 
a t room tem perature as described elsewhere (19). The bromosleeper 
peptide was reduced and alkylated by either of two methods. In m ethod 
1, the peptide was dissolved in 250 mM Tris-HCl, 6 M guanidine hydro­
chloride, and 2 mM EDTA, pH 7.5, reduced w ith a  10% solution of 
£-m ercaptoethanol in  deionized H2O at room tem perature and alky­
lated  in  the dark with a  20% solution of 4-vinyl pyridine in  ethanol. 
W ith m ethod 2 the peptide was reduced with TCEP and alkylated with
4-vinyl pyridine as described previously (20).
Chemical Sequence and Amino Acid Analyses
Automated chemical sequence analysis was performed on a  477A 
Protein Sequencer (Applied Biosystems, Foster City, CA). Amino acid 
analysis was carried out using pre-column derivatization. Approxi­
m ately 500 pmol of the brom oheptapeptide was sealed under vacuum 
with conc. HCl, hydrolyzed a t 110 °C for 24 h, lyophilized and then 
derivatized with o -phthalaldehyde. The derivatized amino acids were 
then  analyzed with HPLC.
Mass Spectrometry
M atrix-assisted laser desorption (MALD) (21) m ass spectra were 
m easured using a  “B ruker REFLEX” (Bruker Instrum ents Inc., Bre­
men, Germany) time-of-flight (22) m ass spectrom eter fitted with a 
gridless reflectron and a N2 laser and a  100-MHz digitizer. An acceler­
a ting  voltage of +31 kV and a  reflector voltage of between 1.16 and 30 
kV were employed for the post source decay FAST (23) m easurem ents. 
The sample (in 0.1% aqueous trifluoroacetic acid) was applied with 
a-cyano-4-hydroxycinnamic acid. Liquid secondary ionization (LSI) (24) 
m ass spectra were m easured using a  Jeol HX110 (Jeol, Tokyo, Japan) 
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age. The sample (in 0.1% aqueous trifluoroacetic acid and 25% aceto­
nitrile) was mixed in  a  glycerol, 3-nitrobenzyl alcohol m atrix  (1:1) and 
analyzed w ith either m agnetic or electric field scans. The spectra were 
calibrated using [Cs(CsI)n] + cluster ions. The LSIMS spectra were 
m easured a t nominal resolutions of either 1000 or 3000. Electrospray 
m ass spectra were m easured using an  LCQ (Finnigan MAT, San Jose, 
CA) ion trap  m ass spectrometer. The samples (in 0.1% aqueous triflu- 
oroacetic acid) were analyzed by direct infusion w ith (bromoheptapep- 
tide) or without (N-term inal 1 -4  fragm ent of the bromosleeper peptide) 
the addition of 20% acetic acid (6:1) solution. The m ass accuracy was 
typically better than: 1000 ppm for the time-of-flight instrum ent in  the 
linear mode, 200 ppm for the time-of-flight instrum ent in  the reflectron 
mode and the ion trap  instrum ent, and 50 ppm for the double focusing 
m ass spectrometer. We note th a t when analyzing Gla-containing pep­
tides w ith time-of-flight m ass spectrometers, decarboxylation can sig­
nificantly reduce the m ass accuracy below these levels (25).
Synthesis of the Bromoheptapeptide
The synthesis was carried out m anually on a 4-methylbenzhy- 
drylam ine resin  using DIC as coupling reagent w ith the Boc protection 
strategy in  DCM w ith the exception of the introduction of the Fmoc 
(9-fluorenylmethoxycarbonyl)-DL-6-bromotryptophan or Fmoc-DL-5-bro- 
m otryptophan. The 4-methylbenzhydrylamine resin  was prepared at 
The Salk Institute, w ith a  substitution of 0.5 mmol/g. The DL-6-bromo- 
tryptophan and DL-5-bromotryptophan were derivatized to Fmoc-DL-6- 
brom otryptophan and Fmoc-DL-5-bromotryptophan, respectively. In the 
case of the Fmoc-DL-6-bromotryptophan-mediated coupling, HOBt/ 
DIEA was used w ith TBTU in N-methylpyrrolidone (NMP) followed by 
the deprotection of the Fmoc group w ith 20% piperidine in  NMP. Four­
fold excess of amino acid derivatives were used in  the coupling reactions 
w ith the exception of the DL-6-bromotryptophan where a  10% excess 
was used. The efficiency of the coupling reactions was checked using the 
Kaiser-ninhydrin test. The dried peptide-resin (1.28 g) was trea ted  with 
15 ml of HF in  the presence of 1.5 ml of anisole a t 0 °C for 1.5 h. After 
the evaporation ofHF, a  first extraction was carried out w ith ether (3 x 
100 ml) and a  second extraction w ith 0.1% aqueous trifluoroacetic acid 
and 60% acetonitrile (3 x  50 ml). Purification of the crude reduced 
product on analytical HPLC indicated two m ajor components whose 
m easured m ass (MALD-MS) were consistent w ith the calculated pep­
tide mass. The extract of the crude peptide (approximately 150 ml) was 
diluted w ith 500 ml of acetic acid, mixed vigorously, and titra ted  with 
iodine in m ethanol (1%) until the color of the solution rem ained amber 
for 10 min. The excess of iodine was elim inated w ith a  5% ascorbic acid 
solution. The volume was reduced by evaporation to 70 ml and the 
residue diluted w ith 430 ml of triethylam ine phosphate, pH 2.25, buffer. 
Acetonitrile was added (approximately 20 ml) until the opalescent liq­
uid tu rned  clear.
The crude brom oheptapeptide solution was clarified by the addition 
of acetonitrile (50 ml) and loaded o n a 4 5  x  320-mm column packed with 
Vydac C ^  15-20-^m  particles and eluted w ith a  W aters PrepLC/Sys- 
tem  500A equipped w ith gradient controller, W aters model 450 variable 
wavelength detector and W aters 1000 PrepPack cartridge cham ber in 
0.1% aqueous trifluoroacetic acid, using a gradient of 60% acetonitrile 
in  0.1% aqueous trifluoroacetic acid. Fractions (50 ml) were collected 
m anually. Two components were isolated, one of them  a t approxim ately 
16% acetonitrile, the other a t approxim ately 22% acetonitrile. The 
collected fractions of the first component (1300 ml) were diluted with 
the same volume of 0.1% aqueous trifluoroacetic acid and reloaded onto 
the equilibrated preparative HPLC column. One m ajor component was 
collected a t approxim ately 22% acetonitrile and lyophilized (34.8 mg, 
purity  based on HPLC 99%, based on CZE 97%). The collected fractions 
of the second component (700 ml) were purified as above. The major 
component was collected a t approximately 26% acetonitrile and lyoph- 
ilized (28.9 mg, purity based on HPLC 99%, based on CZE 97%). 
LSI-MS m easurem ent of both components resulted in  an  intense spe­
cies a t m / z  852.2 consistent w ith the calculated monoisotopic [M + H] + 
m ass of 852.17 Da.
Synthesis o f Bromosleeper N-terminal (1-4) Fragment
The synthesis was in itiated  on Boc-Ile-CM-resin (300 mg), prepared 
a t The Salk Institu te  (1% cross-link, 200-400  mesh, substitution 0.71 
mmol/g). The coupling reactions were carried out m anually using the 
Boc/trifluoroacetic acid protocol w ith DIC in  the case of coupling Boc- 
Thr(OBzl)-OH and Boc-Ala-OH (3 equivalents) in  DCM. The N-termi- 
nal residue DL-6-bromotryptophan was introduced as the N-Fmoc-DL-6- 
brom otryptophan derivative (2 equivalents). The coupling was 
m ediated w ith DIEA/HOBt, and TBTU was used as a  condensing agent
in  NMP. Each coupling reaction was completed w ithin 2 h  and checked 
using the Kaiser-ninhydrin test. The N -term inal Fmoc group was re ­
moved w ith 20% piperidine/NMP in  2 x  10 min. The weight of the 
washed and dried resin  was 390 mg (weight gain 90 mg). The dried 
deprotected peptide-resin (390 mg) was trea ted  w ith 4 ml of HF in the 
presence of 0.4 ml of anisole a t 0 °C for 1.5 h. After the evaporation of 
HF, a  first extraction was carried out w ith e ther 3 x  25 ml) and a  second 
extraction w ith 0.1% trifluoroacetic acid and 60% acetonitrile (3 x  15 
ml) in  water. The fingerprint of the crude product on analytical HPLC 
indicated two m ajor components (diastereom er of the L- or D-6-bromo- 
tryptophan tetrapeptide) w ith observed m asses (MALDI-MS) which 
were consistent w ith the calculated peptide mass.
The purification ofbromosleeper N-term inal (1-4) fragm ent involved 
evaporation of 25% of the aqueous extract (rotavap 38 °C w ater bath). 
The solid residue was redissolved in  3.0 ml of 0.1% aqueous trifluoro- 
acetic acid, 20% acetonitrile buffer and loaded in  0.5 ml portions to a 
sem ipreparative column. The fractions were collected m anually and 
checked by analytical HPLC. The first pooled and lyophilized fractions 
resulted  in  an  8.8-mg peptide th a t was 99.9% pure by CZE, and the 
second fraction resulted  in  a  7.8-mg pure optical isomer tetrapeptide 
w ith 98% purity  by CZE. LSI-MS m easurem ent of both fractions re ­
sulted in  an  intense species a t m / z  568.2, which compared closely w ith 
calculated [M + H]+ monoisotopic m ass of 568.18 Da.
Peptide Characterization
Co-elution o f  N a tu ra l a n d  S yn th e tic  B m m cjheptapeptide—Reverse 
phase HPLC co-elution experiments of n a tu ra l and synthetic bromo- 
heptapeptide were carried out w ith a  Vydac C ^  (5 ^m , 300 A particle 
size) 2.1 x  150-mm column a t a  flow ra te  of 200 ^l/min. Volatile buffers 
(0.055% aqueous trifluoroacetic acid and acetonitrile) were used and the 
effluent was monitored a t 210, 254, and 280 nm w ith a  HP1090 
(Hewlett-Packard, Wilmington, DE).
D eterm ina tion  o f  L- V ersus D -6-Brom otryptophan-containing B rom o­
hep tapep tide—The two purified peptides (corresponding w ith either the 
D- or L-isomers of 6-bromotryptophan) were reduced and alkylated. The 
HPLC-purified reduced and alkylated peptides were lyophilized and 
redissolved in  250 mM Tris base, pH 8.5, and incubated w ith a-chymo- 
trypsin (1:40, 1:10, and 1:5; enzym e:substrate) for up to 9 days. The 
progress of the reaction was monitored w ith HPLC and MALD-MS.
Co-elution o f  N a tu ra l a n d  S yn th e tic  Brom osleeper Peptide N -term i-  
n a l (1 -4) F ra g m en t—Approximately equal am ounts of the endoprotein- 
ase Asp-N-digested N-term inal fragm ent of the bromosleeper peptide 
and the synthetic peptide Trp*-Ala-Thr-Ile-OH were mixed (where Trp* 
= bromotryptophan). The m ixture was applied onto a  C18 analytical 
column and eluted a t 1 m l/min using a  gradient of acetonitrile in 
0.085% trifluoroacetic acid. A sim ilar am ount of the synthetic peptide 
was analyzed on HPLC under the same conditions.
D eterm ina tion  o fL -  VersusD -6-B rom otryptophan in  the Brom osleeper 
P eptide N -term in a l (1 -4 ) F ragm en t—An aliquot (10 ^l) of each syn­
thetic peptide (1 mM) was lyophilized, redissolved in 100 mM Hepes, pH 
7.5, and incubated w ith aminopeptidase-M (1:40; enzym e:substrate) for 
up to 4 days. The progress of the reaction was m onitored w ith HPLC. 
The product of the aminopeptidase-M reaction was co-injected w ith the 
racemic m ixture of 6-bromotryptophan or w ith the racemic m ixture of 
5-bromotryptophan.
RESULTS
Bromoheptapeptide—Two peptides containing L-6-bromo- 
tryptophan were isolated from the venom of predatory Conus 
species. The first was a bromoheptapeptide from C. imperialis, 
purified from a side fraction isolated during the purification of 
another unrelated  peptide a-conotoxin IMI (26) (see Fig. 2). 
Our in terest in th is sample was initially stim ulated after scan­
ning fractions present in the crude venom for novel peptides 
based on the in tact m ass (27), ra the r than  biological activity. 
MALD-MS analysis of the purified fraction indicated species at 
m /z  853, 855, 875, and 879 (data not shown). In order to obtain 
higher m ass resolution w ithout sacrificing sensitivity, this 
sample was analyzed w ith electrospray ionization and an ion 
trap  m ass spectrometer (see Fig. 3A). Several relatively intense 
species were observed w ith 2-Da separation at m /z  835.9 and 
837.9, m /z  853.1 and 855.1, and m /z  875.2 and 877.2, which 
are referred to as doublets. These doublets could be clearly 

























Fig. 2. P u r if ic a t io n  o f  th e  b ro m o h e p ta p e p tid e . Crude venom 
extract was applied on a C18 analytical column and eluted a t 1 ml/min 
w ith a gradient of 1.0% CH3CN/min. The solid  arrow  labeled B H  indi­
cates the fraction containing the brom oheptapeptide, which was subse­
quently re-applied and eluted at 0.22% CH3CN/min. The open arrow  
labeled IM I  indicates the retention time of a-conotoxin IMI previously 
reported to be p resent in C . im peria lis  venom (26).
3A, inset). The separation of approximately 22 Da between m /z  
853.1 and 875.2 (and also between m /z  855.1 and 877.2) sug­
gested competitive [M + H]+ and [M + Na]+ formation (M = 
852). Accordingly, the m /z  835.9 and 837.9 doublets were a t­
tributed to loss of NH3 from the protonated molecule ion. The 
presence of the doublets was characteristic of a molecule con­
taining a single 79Br or 81Br atom. This pattern  of isotopomers 
is quite distinctive, since these isotopes are separated by 2 Da 
and have approximately equal natu ra l abundance, and this 
characteristic doublet was observed from both the synthetic 5- 
and 6-bromotryptophan amino acids (data not shown). Accu­
rate  m ass analysis using LSI on a magnetic sector instrum ent 
was used to determ ine m asses of m /z  853.19 and 855.20 for the 
[M + H]+ doublets (data not shown). It was deduced th a t the 
peptide was N-term inally blocked w ith pyroglutamic acid from 
initial chemical sequencing m easurem ents and the shift in 
chromatographic retention tim e following treatm ent w ith py- 
roglutam ate am inopeptidase. Automated Edm an degradation 
analysis after pyroglutam ate am inopeptidase trea tm en t re­
sulted in the sequence: Cys-Gly-Gln-Ala-X-Cys, where X  indi­
cates a blank cycle. Amino acid analysis confirmed the presence 
of 1 mole ratio of glycine and alanine to 2 mole ratios of 
g lutam ate and cysteine. A major component of the hydrolysate 
eluted 0.7 m in after the expected retention tim e of derivatized 
tryptophan, bu t 2.2 m in before the expected retention time of 
derivatized arginine. After reduction and alkylation of the sam ­
ple w ith iodoacetamide (to form the Cys(Cam) derivative which 
has a residue m ass of 160 Da) MALD-MS analysis revealed two 
sets of doublets a t m /z  991 and 993 and m /z  1007 and 1009 
(see Fig. 3B) separated by 16 Da. We in terpreted these species 
as the [M' + Na]+ and [M' + K]+ of the reduced and alkylated 
peptide (M' = 968 Da). The shift in m ass after reduction and 
alkylation (M' — M = 968-852 = 116 Da) was consistent w ith 
the presence of two cysteine residues. O ther species observed in 
Fig. 3B were in terpreted as fragm ent ions (e.g. m /z  788 corre­
sponds w ith the post source decay b6 fragm ent ion).2 The post-
2 In Fig. 3B, the time-of-flight of the b6 fragm ent ion and therefore the 
observed m / z  788 is slightly lower th an  the calculated m ass (792.2 Da),
Fig. 3. A, electrospray ionization MS of na tu ra l bromoheptapeptide 
between 500 and 1000 Da (inset shows the zoom scan between 850 and 
860 Da) showing a doublet of peaks at m / z  853.1 and 855.1 (cf. calcu­
lated  monoisotopic [M + H]+ of 853.18 Da for the sequence 
ZCGQAW*C-NH2, where Z = pyroglutamic acid and W* = bromotryp- 
tophan); B , MALD-MS of n a tu ra l reduced and alkylated bromohep- 
tapeptide between 700 and 1100 Da; C, MALD post-source delay-MS of 
reduced and alkylated bromoheptapeptide between 100 and 1000 Da 
m easured at low, medium, and high laser power fluences.
source decay FAST spectrum  of the reduced and alkylated 
product, m easured a t low, medium, and high laser power flu- 
ences, are shown in Fig. 3C. In Fig. 3C, the position of the
because th is ion has undergone m etastable decomposition after exiting 
the  source. In Fig. 3C, the FAST spectra are calibrated to compensate 
for the reduced energy of fragm ent ions, and th is procedure results in  a 























F ig. 4. H PLC  c h ro m a to g ra m  o f sy n th e tic  b ro m o h e p ta p e p tid e  
w h e n  p u r if ie d  o n  C 18 re v e rs e  p h a s e  sh o w in g  a  h y d ro p h ilic  a n d  
a  h y d ro p h o b ic  c o m p o n e n t (A), co -e lu tio n  (C18 re v e rs e  p h a se ) of 
h y d ro p h ilic  c o m p o n e n t o f sy n th e tic  b ro m o h e p ta p e p tid e  a n d  
n a tu r a l  b ro m o h e p ta p e p tid e  (B), a n d  p u r if ic a t io n  (C18 re v e rse  
p h a se )  o f th e  p ro d u c ts  fo rm e d  fro m  th e  in c u b a tio n  o f th e  h y ­
d ro p h ilic  c o m p o n e n t o f th e  sy n th e tic  b ro m o h e p ta p e p tid e  w ith  
a -c h y m o try p s in  (C).
monoisotopic [M' + H]+ = 969 is indicated, although only the 
cationized in tact ions were observed. Three fragm ent ions, 
which were observed above the background noise level in the 
low power spectrum  at m /z  793.1, 528.1, and 456.6, were also 
observed a t varying intensities a t medium and high laser 
power. Based on the m ass differences between the paren t and 
the successive fragm ents (176.9, 265.0, and 71.5 Da), we in te r­
preted these ions as corresponding to N-term inal fragm ents 
differing in m ass by Cys(Cam), X , and Ala where X  = 265 Da. 
We conclude th a t these three fragm ent ions (b6, b5, and b4) 
encompass the blank observed in the chemical sequence data. 
Based on these results we deduced th a t the 6th  amino acid, was 
hydrophobic, absorbed intensely a t 280 nm, and had a m ass of
Fig. 5. P u r if ic a t io n  o f th e  b ro m o s le e p e r  p e p tid e . A, crude 
venom extract was applied on a C18 sem ipreparative column and eluted 
at 5 ml/min w ith a gradient of 0.45% CH3CN/min. B, the bioactive 
fraction denoted “BS” was applied onto a C18 analytical column and 
eluted a t 1 ml/min using a gradient of 0.18% CH3CN/min. C, the  peak 
indicated by the  arr ow  in B  was repurified at 1  ml/min w ith a gradient 
of 0.9% CH3CN/min to obtain the bromosleeper peptide.
265 Da. We proposed the sequence: Pca-Cys-Gly-Gln-Ala-Trp*- 
Cys-NH2 (where Pca = pyroglutamic acid and Trp* = bromo­
tryptophan). The calculated [M + H]+ for the monoisotopic 
m ass of the bromoheptapeptide (853.176 Da) was consistent 
w ith the m easured m /z  of 853.19 (see Fig. 3A).
Assignment of bromotryptophan was confirmed by total 
chemical synthesis of the bromoheptapeptide. The synthesis of 
bromoheptapeptide using a racemic m ixture of the D and L 
forms of 6-bromotryptophan resulted in two diastereomeric 
peptides, one containing the D configuration 6-bromotrypto- 
phan a t position 6, while the other containing the L configura­
tion 6-bromotryptophan a t position 6. HPLC purification of the 
crude synthesis product indicated the presence of a hydropho­
bic and a hydrophilic species (see Fig. 4A), both of which con­
tained the characteristic doublet a t m /z  853.2 and 855.2 con­
sistent w ith the native bromoheptapeptide based on LSI-MS 
analysis (data not shown). The separation of the peptides con­
tain ing a D versus an L amino acid by reverse phase HPLC 
exploits structural differences th a t attend  chiral inversion at 
the Ca atom. The hydrophilic isomer co-eluted w ith the natural 
peptide on HPLC (see Fig. 4B). The susceptibility of the mod­
ified tryptophan residue toward enzymatic hydrolysis after 
reduction and alkylation of the cysteine residues was deter­
mined by incubation of the synthetic peptide w ith a-chymo- 
trypsin. The hydrophilic isomer was observed to hydrolyze 
when incubated w ith a 1:10 enzyme to substrate ratio w ithin 2 
days (see Fig. 4C), w hereas the hydrophobic isomer underw ent 
no hydrolysis a t th is enzyme to substrate ratio  when incubated 
for 9 days (data not shown). The in tact mass and isotopomer 
distribution for the chymotrypsin-hydrolyzed fragm ent an a­
lyzed w ith LSI-MS corresponded w ith the calculated mass for 
the reduced and alkylated 1 -6  bromoheptapeptide fragm ent 
(Pca-Cys(Cam)-Gly-Gln-Ala-Trp*-OH; calculated monoisotopic 
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Table I
Biological effects o f  the brom osleeper peptide  
Varied doses of purified peptide dissolved in  norm al saline were injected intracranially  into mice. Two to th ree  mice were used per dose. Note 
th a t the bromoheptapeptide is not active in th is assay.
Dose
Observed effects
9-Day-old mice 17-Day-old mice 22-Day-old mice





Slept for ~  1 h  
Slept for >  10 h 




~11 min, slept for ~ 4  h
Lethargic/drowsy after ~  19 min 








a —, not tested.
(data not shown)).
Although bromine is typically incorporated at position 6 in 
m arine products, in order to unambiguously resolve the ques­
tion of the stereochemistry of this modified amino acid, we 
synthesized the bromoheptapeptide w ith the racemic m ixture 
of D- and L-5-bromotryptophan. This peptide did not co-elute on 
HPLC w ith the na tu ra l bromoheptapeptide (data not shown).
Insufficient native bromoheptapeptide was available for te s t­
ing biological activity. Synthetic bromoheptapeptide was as­
sayed for biological activity by injecting 20 nmol of peptide 
either in tracranially  or intraperitoneally into mice. No gross 
behavioral changes in activity were observed, and this peptide 
was not fu rther tested for biological activity.
Bromosleeper Peptide—Concurrent w ith the investigation of 
the bromoheptapeptide we also characterized a novel “sleeper” 
peptide, which induces a sleep-like state in mice; th is peptide 
was purified from C. radiatus venom (peak B S  of Fig. 5A). In 
the subsequent purification steps using an analytical HPLC 
column, the sleeper activity coincided w ith the major peaks 
shown in Fig. 5, B  and C .
A family of peptides which elicit a sleep-like state in mice, 
the conantokins, have been described previously from Conus 
venoms. The peptide isolated from C. radiatus  was very differ­
ent from the conantokins w ith respect to activity profile; 
whereas the conantokins cause sleep when injected in tracran i­
ally in very young mice (<2 weeks old) and hyperactivity in 
older mice (>3 weeks old), the new peptide induced sleep in 
mice of both age groups. A sum m ary of the in vivo effect of the 
purified peptide is shown in Table I. It is obviously more potent 
in 9-day-old mice than  in the older mice; the effective dose is 
lower, the onset tim e is shorter, and the duration of sleep is 
longer in younger mice.
MALD-MS analysis of the purified fraction m easured in the 
linear mode indicated a broad species a t m /z  3884 in contrast 
to the m easurem ent in the reflectron mode of m /z  3729. 
LSI-MS analysis of the same sample indicated a species a t m /z  
3916.4 (data not shown). These results suggested th a t the 
peptide contained a num ber of Gla residues (25). Chemical 
sequencing after reduction and pyridylethylation of the cys­
teine residues gave no regular phenylthiohydantoid derivative 
of an amino acid a t cycle one but an intense signal for alanine 
a t cycle two followed by normal repetitive recovery. W eak sig­
nals were also observed a t positions 6, 8, and 9. Endoproteinase 
Asp-N hydrolysis of the bromosleeper peptide generated three 
major fractions, which when subm itted to chemical sequence 
analysis revealed the following sequences: (i) X-Ala-Thr-Ile; (ii) 
Asp-X-Cys-X-X-Thr-Cys-Asn-Val-Thr-Phe-Lys-Thr-Cys-Cys- 
Gly-Hyp-Hyp-Gly, and (iii) Asp-Trp-Gln-Cys-Val-X-Ala-Cys- 
Pro-Val; where X  indicates a blank cycle. Endoproteinase 
Lys-C hydrolysis generated two fragm ents th a t after mass 
spectrometry and chemical sequence analysis could be used to 
deduce the connectivity of the three Asp-N fragm ents as (i) 
1-4 , (ii) 5-23, and (iii) 24-33. Based on m ass spectrometric 
analysis of the Asp-N fragm ents 5-23 and 24-33, the weak
Fig. 6. E le c tro sp ra y  io n iz a tio n  MS zoom  scan  o f th e  N -te rm i- 
n a l  1 -4  f ra g m e n t o f  th e  n a tu r a l  b ro m o s le e p e r  p e p tid e  b e tw e e n  
563 a n d  573 D a sh o w in g  a  d o u b le t  o f p e a k s  a t  m /z  568.1 a n d  570.1 
(cf. c a lc u la te d  m o n o iso to p ic  [M + H ]+ o f 568.177 D a fo r  th e  
se q u e n ce  W*ATI, w h e re  W* = b ro m o try p to p h a n ).
signals a t 6, 8, 9, and 29 were in terpreted as Gla residues. The 
accurate m ass of the 24-33 fragm ent indicated th a t the C 
term inus of the peptide was in the free acid form (data not 
shown). We noted a strong UV absorption a t 280 nm for both 
the in tact peptide and the N-term inal fragm ent characteristic 
of an indole group. Although it was reasonable to expect such 
absorption from the in tact peptide th a t contains tryptophan, in 
the case of the 1 -4  fragm ent th is adsorption was attribu ted  to 
the residue in position 1. Electrospray ionization ion trap  m ass 
spectral analysis of the N-term inal 1 -4  fragm ent revealed a 
weak (but constant) signal which when accumulated over sev­
eral m inutes resulted in a doublet of peaks a t m /z  568.1 and 
570.1; the zoom scan of which is shown in Fig. 6. LSI-MS 
analysis of the N-term inal 1 -4  fragm ent (after esterification 
w ith hexanol to optimize the sensitivity of LSI analysis; resu lt­
ing in addition of 84 Da) also resulted in a weak signal where 
a doublet a t m /z  652.27 and 654.26 could be observed which 
was not present when the m atrix  alone was analyzed (data not 
shown). We noted the sim ilarity between the isotopomer in ten­
sities of the doublet observed in Fig. 6 and th a t observed for the 
bromoheptapeptide (see Fig. 3A, inset) and the synthetic bro- 
m otryptophan amino acids. The properties of the modified 
amino acid were consistent w ith the presence of bromotrypto- 
phan; e.g. the observed m /z  of 652.27 was consistent w ith the 
calculated monoisotopic m ass for the [M + H]+ of the 1 -4  
fragm ent Trp*-A-T-I-C6H12 (652.271 Da). We therefore pro­
posed the sequence Trp*-Ala-Thr-Ile-Asp-Gla-Cys-Gla-Gla- 
Thr-Cys-A sn-V al-Thr-Phe-Lys-Thr-C ys-C ys-G ly-H yp-H yp- 
Gly-Asp-Trp-Gln-Cys-Val-Gla-Ala-Cys-Pro-Val-OH (where 
Hyp = hydroxyproline, Gla = y-carboxy glutam ate, and Trp* = 
bromotryptophan).
After synthesis of the bromosleeper peptide 1 -4  N-term inal 

























Fig. 7. H PLC  c h ro m a to g ra m  (C18 re v e rs e  p h a se )  o f  sy n th e tic  
b ro m o s le e p e r  N -te rm in a l 1 -4  f ra g m e n t c o n ta in in g  a  ra c e m ic  
m ix tu re  o f  th e  D  a n d  L fo rm s o f  6 -b ro m o try p to p h a n  sh o w in g  
h y d ro p h ilic  a n d  h y d ro p h o b ic  c o m p o n e n ts  (A), co -e lu tio n  (C18 
re v e rs e  p h a se ) o f h y d ro p h ilic  c o m p o n e n t o f  sy n th e tic  a n d  n a t ­
u r a l  N -te rm in a l f ra g m e n t (B), a n d  p u r if ic a t io n  (C18 re v e rs e  
p h a se )  o f  th e  p r o d u c ts  fo rm e d  fro m  th e  in c u b a tio n  o f th e  h y ­
d ro p h ilic  c o m p o n e n t o f th e  sy n th e tic  N -te rm in a l f ra g m e n t w ith  
a m in o p e p tid a se  M (C ).
6-bromotryptophan, a hydrophobic and a hydrophilic peptide 
isomer were purified (see Fig. 7A). LSI-MS analysis of both the 
hydrophobic and the hydrophilic peptide isomer resulted in 
m ass spectra consistent w ith th a t of the native 1 -4  bro­
mosleeper fragm ent (data not shown). The hydrophilic isomer 
was found to co-elute w ith the natu ra l peptide on HPLC (see 
Fig. 7B). The susceptibility of the bromotryptophan residue 
toward enzymatic hydrolysis was determ ined by incubation of 
the synthetic peptide w ith aminopeptidase-M. The hydrophilic 
isomer was observed to hydrolyze w ithin 24 h (see Fig. 7C), 
whereas the hydrophobic isomer underw ent no hydrolysis un ­
der the same conditions or when incubated for 4 days. The
brom otryptophan amino acid released from the hydrophilic 
isomer co-eluted on HPLC w ith the racemic m ixture of 6-bro- 
m otryptophan bu t did not co-elute w ith the racemic m ixture of 
5-bromotryptophan (data not shown).
DISCUSSION
We report the purification of two peptides from venoms of 
two species of cone snails th a t are divergent from each other, 
both in their morphology and the feeding biology. The two 
peptides from these d isparate  venoms are not homologous 
to each other, bu t unexpectedly, we have found th a t they 
share one novel biochemical feature, the presence of 
L-6-brom otryptophan.
The first peptide characterized was a heptapeptide isolated 
from the venom of the imperial cone, C. imperialis, which hunts 
polychaete worms. The bromoheptapeptide exhibited no gross 
peripheral or central symptoms when injected into mice; its 
biological activity in m arine annelid systems has yet to be 
assessed. The bromoheptapeptide incorporates three post- 
translational modifications other than  bromotryptophan (pyro- 
glutamic acid, disulfide bridge, and am idated C term inus). We 
know of only a few other peptides th a t contain pyroglutamic 
acid, a disulfide bridge, and an am idated C term inus (e.g. 
tunicate gonadotropin releasing hormone II from Cheylosoma 
productum  (28)), emphasizing the highly modified nature of the 
bromoheptapeptide.
In contrast to the worm -hunting C. imperialis, the radial 
cone, C. radiatus, is a deep w ater Indo-Pacific fish-hunting 
cone snail. The 33-residue bromosleeper peptide isolated from 
C. radiatus venom induces a sleep-like state when injected 
centrally into mice, symptomatology rem iniscent of the biolog­
ical effects of the conantokins, a well characterized Conus pep­
tide family which inhibits the N -methyl-D-aspartic acid recep­
tors (29-33). However, the bromosleeper peptide differs from 
the conantokins in th a t it induces a sleep-like state in mice of 
all ages (conantokins cause sleep in young mice under 2 weeks 
of age; mice older than  3 weeks exhibit a climbing syndrome). 
For the bromosleeper peptide, no climbing syndrome is ob­
served a t any age.
The num ber of post-translational modifications in the bro- 
mosleeper peptide is also noteworthy: in addition to having 
brom otryptophan, the bromosleeper peptide has three disulfide 
bridges, 4 residues of Y-carboxyglutamate (formed by the v ita ­
min K-dependent post-translational carboxylation of g lu ta­
m ate residues) and 2 hydroxyproline residues. Furtherm ore, 
there clearly is selectivity w ith respect to the bromination 
reaction; only Trp (1) is brom inated, while Trp (25) is unmod­
ified. This selectivity in bromination suggests a Trp-bromina- 
tion signaling site to direct the modification enzyme to a spe­
cific tryptophan residue.
Evidence for L-6-Bromotryptophan as a Secondary Amino  
Acid—To our knowledge, L-6-bromotryptophan has neither 
been reported among the numerous peptides previously char­
acterized from a variety of species of Conus venoms nor from 
any other natu ra l peptides/proteins. Thus, the discovery of this 
amino acid residue in Conus peptides both establishes L-6- 
brom otryptophan as a proteinogenous amino acid and unequiv­
ocally dem onstrates th a t tryptophan can be a precursor for a 
secondary amino acid in eukaryotic systems.
In order to minimize the erroneous labeling of modified 
amino acids as proteinogenous, guidelines w ith specific criteria 
have been proposed (10) for acceptance of new proteinogenous 
amino acids. Unfortunately, these guidelines are not always 
infallible and have not circumvented the inappropriate accept­
ance and subsequent w ithdraw al of residues such as ^-hy- 
droxyglutamic acid and norleucine as proteinogenous amino 
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Table II
M arine com pounds con ta in ing  a  b rom ina ted  indole group
Origin Species Compound Peptidic #a Ref.
Sponge P achym atism a  johnston i and 
A p ly s in a  sp.
D-6-Bromohypaphorine No 6 51, 52
Sponge Sm enospongia  aurea 6-Bromoaplysinopsin No 6 53
Sponge H am a ca n th a  sp. Ham acanthins A and B No 6 54
Sponge G ellius sp. and O rina  sp. Gellusines A and B No 6 55
Sponge D ragm acidin  sp. and H exadella  sp. (±)-Dragm acidin and dragmacidon B No 6 56-58
Bryozoa F lustra  foliacea Flustram ine, flustrabrom ine, and 
flustrarine B
No 6 59-61
Sponge Ja sp is  sp. D-N -Methyl-2-bromotryptophan Yes 2 47
Sponge L issoclinum  sp. Lissoclins C No 6 62
Tunicate E u syn stye la  m isa k ien sis Eusynstyelamide Yes 6 48
Shellfish B abylon ia  japonica Surugatoxin and neosurugatoxin No 6 63, 64
Tunicate H alocyn th ia  roretzi Halocyamines A and B Yes 6 49
Tunicate E u d is to m a  o livaceum , R itterella  
s ig illino ides , E u d is to m a  
fra g ru m , E u d is to m a  glaucus
Eudistomines, eudistomin K sulfoxide, 
woodinine, and eudistomidins
No 5, 6, 7 65-70
Tunicate D id em n u m  can d id u m 6-Bromotryptamine, 2,2-bis(6' -bromo-3' - 
indolyl)ethylamine, and 2,5-bis(6'- 
bromo-3' -indolyl)piperazine
No 6 71
Sponge Sm enospongia  echina 5,6-Dibromo-N,N-dimethyltryptamine No 5, 6 72
Acorn worms E nteropneusta 6-Bromo-3-chloroindole No 6 73
Algae Larencia  brongniartii 2,3,5,6-Tetrabromindole No 2, 3, 5, 6 74
Sponge Iotrochota  sp. Methyl-3-(6-bromoindol-3-yl)prop-2-enoate No 6 75
Mollusk M uriceidea prosobranchial 6,6'-Dibromoindigo No 6 76
a Position of bromine substitution.
amino acids as proteinogenous highlights the difficulties th a t 
may be encountered in  determ ining the natu re  of modified 
amino acids. MS techniques have been used previously to re­
duce possible ambiguities in the determ ination of a new amino 
acid (12). In  contrast to the proteinogenous amino acids th a t 
were identified after using acid or base hydrolysis to liberate 
the amino acid, orthogonal techniques for sequence determ ina­
tion of peptides (34, 35) have allowed the unam biguous iden­
tification of the brom otryptophan amino acid residue. In p a r­
ticu lar, the MS sequence experim ent provided sequence 
information encompassing the modified amino acid. As a re­
sult, we can exclude the possibility of hydrolysis introducing 
some chemical modification.
Previously proposed criteria (11), which have been fulfilled 
for classification of this modified amino acid as proteinogenous, 
are as follows.
(i) The complete sequences of two peptides th a t contain this 
post-translationally modified amino acid have been character­
ized. In addition, the sequence of a third novel bromotryptophan- 
containing peptide, bromocontryphan,3 has been determined.
(ii) The complete synthesis of the bromoheptapeptide and the 
synthesis of the N -term inal te trapeptide fragm ent of the bro- 
mosleeper peptide have been carried out using a racemic mix­
ture of 6-bromotryptophan. After synthesis of the peptides, it 
has been possible to resolve and thereby purify each 6-bromo- 
tryptophan-containing peptide (see Figs. 4A and 7A). The pu­
rified synthetic hydrophilic isomer of the bromoheptapeptide 
has been shown to co-elute w ith the na tu ra l bromoheptapep- 
tide (see Fig. 4B). The purified synthetic hydrophilic isomer of 
the N-term inal 1 -4  fragm ent of the bromosleeper peptide has 
been shown to co-elute w ith the natu ra l bromosleeper peptide 
1 -4  fragm ent (see Fig. 7B).
(iii) The purified hydrophilic synthetic isomer of the bromo- 
heptapeptide has been identified as the L conformation on the 
basis of the ability of a-chym otrypsin to cleave the peptide 
(see Fig. 4C). The purified synthetic hydrophilic isom er of the 
N -term inal 1 -4  fragm ent of the brom osleeper peptide has 
been identified as the L conformation on the basis of the
3 Jim enez, E. C., Craig, A. G., W atkins, M., Hillyard, D. R., Gray, W.
R., Gulyas, J., Rivier, J. E., Cruz, L. J., and Olivera, B. M. (1997) 
B iochem istry , in  press.
ability of am inopeptidase-M  to cleave the N -term inal residue 
from the te trapep tide (see Fig. 7C), and the fragm ent was 
observed to co-elute w ith  the racemic m ixture of 6-bromo- 
tryp tophan  under conditions th a t distinguish  th is  amino acid 
from 5 -brom otryptophan.
It is also noteworthy th a t the sequence of a cDNA clone 
encoding the bromosleeper peptide from C. radiatus has been 
determ ined.4 The m ature peptide purified from venom is en­
coded a t the extreme C-term inal end of the predicted pre­
propeptide precursor. The brom otryptophan residue is encoded 
in the mRNA by the codon for tryptophan. We presum e th a t the 
polypeptide precursor for the bromosleeper peptide has a nor­
mal L-tryptophan after the prim ary translation  event. A mod­
ification system then specifically brom inates Trp (1) of the 
bromosleeper peptide (most probably this modification takes 
place before the m ature peptide is proteolytically cleaved from 
the precursor) resulting in  a L-6-bromotryptophan residue.
Brominated Conus Peptides in the General Context ofBrom i- 
nated Am ino Acids and N atural Products—A wide variety of 
haloperoxidases are known th a t can brom inate tyrosine resi­
dues in hum ans and animals, including myeloperoxidases and 
lactoperoxidases (4). In addition, bromoperoxidases have been 
isolated from several species of algae (4,36).
Post-translationally iodinated (1, 37-40, 41), chlorinated 
(42-44), and brom inated (45,1 44) tyrosine residues have been 
isolated from a variety of m arine specimens. Although it has 
been suggested th a t there m ust be other halogenated amino 
acid residues than  tyrosine in sponges, none have been posi­
tively identified.
The brom ination of tryptophan or its derivatives appears to 
occur widely in m arine organisms. Brominated indole deriva­
tives have been characterized in a wide variety  of marine 
natu ra l products over a broad phylogenetic range (from m arine 
algae to vertebrate systems). The rem arkable diversity of m a­
rine na tu ra l products containing indole derivatives is briefly 
sum m arized in Table II (see Ref. 46 for other brom inated m a­
rine products). Of the brom inated compounds isolated from 
m arine products, only jaspam ide (47), eusynstyelamide (48), 
halocyamine A, and halocyamine B (49) contain brom inated
















Identification of Brom otryptophan in Conus Peptide Toxins 4697
indole groups w ithin a peptidic framework. Jaspam ide is a 
metabolite of mixed peptide polyketide biosynthetic origin 
which has been proposed as a cyclic depsipeptide made up of 3 
amino acids and an octyl ketide group (47). Eusynstyelam ide is 
an extremely polar molecule isolated after m ethanol extraction 
which has been proposed to be a highly modified peptide dimer 
where each monomer is made up of two modified amino acids 
and a guanidinyl-amide group (41). Halocyamine A and B are 
modified peptidic structures where both (A and B) contain 
three residues, 2 of which are common amino acids (49). The 
structure of the L-6-bromotryptophan amino acid observed in 
the bromoheptapeptide and the bromosleeper differs from the 
D-N -methyl-2-bromotryptophan in jaspinamide, the bromoin- 
doyl group in eusynstyelamide and the modified bromodidehy- 
drotryptam ine found in the halocyamines. However, the major 
difference is th a t neither jaspinamide, eusynstyelamide, nor 
the halocyamines are purely peptidic structures. Although the 
cyclic structure of jaspinam ide does incorporate one other com­
mon amino acid (alanine), it is better described as a hybrid 
polyketide/polypeptide. Eusynstyelam ide is also not a true pep­
tide structure, and although a case can be made th a t it incor­
porates a modified arginine amino acid and modified trypto­
phan, the structure is more correctly a bromoindoyl-succinic 
acid-guanidinyl-amide. The halocyamines A and B are closest 
in structure to peptidic, containing histidyl, threonyl, glycy, 
and dihydroxy phenylalanyl residues linked a t the C term inus 
to the 6-bromo-8,9-didehydrotryptamine group. However, the 
bromodidehydrotryptamine is a C-term inal modification ex­
tending a tripeptide ra th e r than  a fourth amino acid. Thus, 
neither jaspinamide, eusynstyelamide, nor the halocyamines 
are the resu lt of mRNA transcription, and therefore the resu lt­
ing modified bromoindole groups present in these molecules 
cannot be considered as proteinogenous amino acids. With the 
exception of D-N-methyl-2-bromotryptophan, all of the molecules 
listed in Table II involve bromine substitution at position 6 (and 
in some cases at additional sites) of the indole ring. On the basis 
of these observations a general rule for incorporation of bromine 
at position 6 in marine organisms has been proposed (50).
Some of the great diversity of m arine natu ra l products con­
taining brom inated indole derivatives are likely to be defensive 
compounds w ith strong pharmacological activity, particularly 
those from sessile m arine organisms which rely strongly on 
their chemical defenses. Thus, although bromination has been 
reported from a very diverse group of biologically active com­
pounds, it has not previously been dem onstrated th a t a bromi- 
nated  tryptophan occurs in a regular polypeptide structure. 
However, given th a t the cone snails have developed an am az­
ing brew of potent antagonists, it is perhaps not surprising th a t 
as m arine organisms, they have recruited brom ination as a 
m eans of increasing their peptidic repertoire. In effect, they 
may have recruited brom ination in much the same way as 
other m arine organisms have used brom ination for generating 
pharmacologically active natu ra l products.
Thus, if the cone snails have indeed evolved brom ination of 
tryptophan as a novel adaptation in their venom ducts, it would 
not be difficult to see potential interm ediate steps in the gen­
eration of such a system. The broad distribution of brom inated 
natu ra l products in the m arine environm ent presum ably arises 
through a broad spectrum  of bromo- and lactoperoxidases in 
m arine organisms. If a bromoperoxidase were recruited to be­
come sequence-specific, it would become a post-translational 
modification enzyme, only catalyzing the bromination of spe­
cific tryptophan residues in a polypeptide structure, such as 
apparently occurs for the bromosleeper peptide. Thus the oc­
currence of L-6-bromotryptophan in Conus peptides could be 
due to an adaptation involving the recruitm ent of an enzymatic
system already generally distributed among m arine organ­
isms; the cone snails have used th is more general bromination 
chemistry evolved in m arine ecosystems in a specialized way in 
their venom ducts.
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